Drug · DIN 02243237
RAPAMUNE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since June 10, 2013; first marketed May 15, 2001.
- Drug Identification Number (DIN)
- 02243237
- Company (DIN owner)
- Pfizer Canada UlcKirkland, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Solution
- Route
- Oral
- Therapeutic class (ATC)
- Sirolimus L04AH01
- Class
- Human
- Record last updated
- June 15, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| SIROLIMUS | 1 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- October 8, 2010: NOC 11800New Drug Submission (NDS) · Manufacturer name change
- March 10, 2003: NOC 3580New Drug Submission (NDS) · Manufacturer name change
- January 5, 2001: NOC 2597New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “rapamune”. A notice may cover another product or only some lots: read it to see what it covers.
- Archived - Rapamune (sirolimus) - Blood Level Measurement Changes - For the PublicDecember 2, 2009 · Drugs
- Rapamune (sirolimus) - Blood Level Measurement Changes - For Health ProfessionalsDecember 2, 2009 · Drugs
- Archived - New warning regarding RAPAMUNE® (sirolimus) and Bronchial Anastomotic Dehiscence including fatal cases by Wyeth PharmaceuticalsFebruary 23, 2009 · Health products
Other DINs named RAPAMUNE
- DIN 02247111 · Marketed
- DIN 02270617 · Cancelled Pre Market
- DIN 02270684 · Cancelled Pre Market